摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[(2,6-dimethylpyridin-3-yl)methylamino]-6-[(3S)-3-(5-methoxypyridin-2-yl)-2-methylbutoxy]-2-methylpyridazin-3-one

中文名称
——
中文别名
——
英文名称
4-[(2,6-dimethylpyridin-3-yl)methylamino]-6-[(3S)-3-(5-methoxypyridin-2-yl)-2-methylbutoxy]-2-methylpyridazin-3-one
英文别名
——
4-[(2,6-dimethylpyridin-3-yl)methylamino]-6-[(3S)-3-(5-methoxypyridin-2-yl)-2-methylbutoxy]-2-methylpyridazin-3-one化学式
CAS
——
化学式
C24H31N5O3
mdl
——
分子量
437.5
InChiKey
UTFDTSITTRZFJT-LWKPJOBUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    32
  • 可旋转键数:
    9
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    88.9
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • [EN] SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDIZINONE SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA PDE10
    申请人:MERCK SHARP & DOHME
    公开号:WO2014139150A1
    公开(公告)日:2014-09-18
    The present invention is directed to substituted pyridizinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    本发明涉及一种具有式(I)的取代吡啶酮化合物,其可用作治疗与磷酸二酯酶10(PDE10)相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这种化合物治疗神经学和精神疾病,如精神分裂症、精神病或亨廷顿病,以及与纹状体功能不足或基底节功能障碍相关的疾病。
  • [EN] SUBSTITUTED PYRIDIZINONE DERIVATIVES AS PDE10 INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDIZINONE SUBSTITUÉS EN TANT QU'INHIBITEURS DE PDE10
    申请人:MERCK SHARP & DOHME
    公开号:WO2014150114A1
    公开(公告)日:2014-09-25
    The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
查看更多